Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 8971 results

  1. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued Reference number: GID-TA10891

    Technology appraisal guidance
    Discontinued

  2. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued Reference number: GID-TA10750

    Technology appraisal guidance
    Discontinued

  4. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued Reference number: GID-TA10830

    Technology appraisal guidance
    Discontinued

  5. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued Reference number: GID-TA10870

    Technology appraisal guidance
    Discontinued

  6. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  7. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

    Technology appraisal guidance
    Discontinued

  8. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued Reference number: GID-TA11262

    Technology appraisal guidance
    Discontinued

  9. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  12. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued

  13. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued Reference number: GID-TA11177

    Technology appraisal guidance
    Discontinued

  14. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued Reference number: GID-TA11179

    Technology appraisal guidance
    Discontinued

  15. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued Reference number: GID-TA11180

    Technology appraisal guidance
    Discontinued